Loading, Please Wait...
MISSION VIEJO, Calif., Sept. 11, 2018 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (NASDAQ: MYND), a market leader in improving the delivery of mental health through the combination of telemedicine and data analytics/augmented intelligence, today announced that its wholly owned subsidiary, Arcadian Telepsychiatry Services LLC, has launched a new program to offer, through its network of providers, inmates of correctional facilities with access to telepsychiatry, teletherapy and other mental health services. Telepsychiatry involves the use of video conferencing equipment to conduct real time mental health consultations between a clinician and a patient. This program is designed to benefit correctional facilities with limited access to mental health providers, as well as reduce costs and provide access to services in a safe and convenient manner for both the healthcare provider and inmate.
Robert Plotkin, CEO and Founder of Arcadian, stated, “Within many correctional facilities across the country, inmates often have limited access to mental health services versus the general population. These individuals have traditionally been underserved due to inaccessibility and safety concerns, as well as lack of providers since many of the facilities are located in rural and remote areas. Tragically, many of these inmates are in dire need of services and suffer from high rates of mental illness, which often contributed to their incarceration. In other cases, mental illness may develop or get exacerbated from the stresses of incarceration. Left unattended, these inmates have a higher risk of recidivism. Telepsychiatry addresses these problems. Studies affirm that telepsychiatry is as effective as in-person treatment for a wide variety of mental healthcare issues. Some patients even prefer remote service as opposed to in-person service, citing the ease of establishing rapport between the provider and patient. We look forward to launching our program with correctional facilities nationwide.”
George Carpenter, CEO of MYnd Analytics, commented, “The National Bureau of Justice has reported that more than 50% of inmates in correctional facilities had a diagnosable mental illness. Additionally, those inmates with mental illness are much more likely to reenter the correctional system within 3 years of release. With so many mentally ill inmates being released and reoffending, correctional system administrators and providers have had to examine ways to effectively treat mental illness and to decrease recidivism among the mentally ill. By combining our telemedicine platform with MYnd’s Peer report, we can reduce trial and error prescribing in mental health, which will not only help improve outcomes, but also patient compliance. We strongly believe this new combined offering will provide inmates greater access to mental health services, resulting in lower reincarceration rates and a positive impact across communities.”
Arcadian Telepsychiatry Services LLC manages a suite of services including telepsychiatry, teletherapy, digital patient screening, curbside consultation, on-demand services, and scheduled encounters for all age groups. Arcadian utilizes patient engagement and re-engagement strategies so that care is effectively completed, helping to comfortably move inpatient care to outpatient, assisting patients in readjusting to their life routine, as well as reducing wait times for mental health treatment. Arcadian’s customer base includes major health plans, health systems, and community-based organizations.
About MYnd Analytics
MYnd Analytics, Inc. (www.myndanalytics.com) is a predictive analytics company that has developed a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients. The Company’s Psychiatric EEG Evaluation Registry, or PEER Online, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Company’s original physician-developed database, there are now more than 39,000 outcomes for over 11,000 unique patients in the PEER registry. The goal of PEER Online is to provide objective, personalized data to assist physicians in the selection of appropriate medications.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit: www.myndanalytics.com.
Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements involve risks and uncertainties, such as statements regarding market developments, new products and growth strategies, Arcadian's ability to reduce patient suffering through increased access to care, Arcadian's ability to use MYnd’s data analytics capabilities to successfully reduce trial and error prescribing, advantages offered by telemedicine, the ability of MYnd’s and Arcadian's products to successfully target objectivity and increased efficiency in the treatment of depression and other mental health and psychiatric illnesses, as well as those risks and uncertainties set forth in MYnd's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
Crescendo Communications, LLC
Tel: +1 (212) 671-1020